|
|
 |
|
Viewing report
|
|
|
|
Therapeutic Cancer Vaccines: Evolving Strategies and Pipeline Prospects
Greystone Associates, July 2008
Efforts to up-regulate the human immune system to recognize and destroy tumor cells with minimal side effects and collateral damage to healthy tissue continue to attract a mixture of optimism and determination from vaccine developers. Despite a number of setbacks, about three dozen companies are actively pursuing therapeutic cancer vaccines (TCVs), with vaccine candidates in various stages of clinical trial. Over the past thirty-six months, there has been a shift in the source of antigens for TCVs, with a steep drop in the number of TCVs based on allogeneic tumor cells. About half of the companies with TCVs currently in clinical trials have opted to use engineered antigens, which they administer via transfected DNA in a host vector or deliver either as fusion proteins or encapsulated in synthetic particles. About a dozen developers are employing autologous tumor extracts as a source of epitopes. Extended time lines and challenging trial end points continue to pose significant challenges in this sector.
Therapeutic Cancer Vaccines: Evolving Strategies and Pipeline Prospects is a comprehensive analysis and assessment of therapeutic vaccines being developed for the treatment of human cancers. This is an in-depth examination of the current technology, business, strategic, regulatory and commercialization factors that define this closely-watched segment
Technology - Examines more than fifty development-stage candidates, including vaccine technology, vaccine design, processing, manufacturing, and patient administration.
Development – Clinical trial progress, including strategies, protocols, endpoints and trial outcomes
Business – Company focus, tactical approach, financial resources, human capital, alliance strategy, operational risks
Regulatory – Evolving approach to therapeutic vaccines, regulatory sector initiatives, approvalfactors
Commercialization – Risk factors, manufacturability, strategic factors, competitive landscape by indication
Key Value Elements
- Cancer Therapeutics Opportunity/Risk Assessment
- Vaccine Technology Platform Evaluations
- Product Development & Clinical Trial Status
- Immune Response Target Assessment
- Market Structure
- Business Strategies
- Cancer Vaccine Segment Analysis
- Alliance/Partnership Assessment
- Market Potential Sensitivity Analysis
- Strategic Positioning
- Proprietary Technology
- Technology Factors
- Market Factors
- Regulatory Factors
Customers who bought this item also bought
Cancer Vaccines and Tumor Immunity
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines
Building Better Cancer Vaccines: The Progress and Promise of R&D
Cancer Vaccine Developments to 2013 + Cancer Vaccine Tracker
Pipeline Insight: Therapeutic Cancer Vaccines - A Turbulent Path from Bench to Bedside
Human Vaccines - Global Strategic Business Report
Outlook for Cancer Vaccine Development
Therapeutic Vaccines for Cancer: On the Threshold of Success
Cancer Vaccine Developments to 2013
Pipeline Insight: Cancer Vaccines and Cell Therapies - Technical Know How Needs Translation Into Clinical and Commercial Rewards
Stakeholder Opinions: Vaccine Adjuvants - Uncertainties Rule
Therapeutic Vaccines: More Trials and Tribulations
|
|
|
|
